Phase 2 N=36 Open-Label CA-008 (Vocacapsaicin) in Bunionectomy
Pain
Primary: Area Under the Curve (AUC) of Numerical Rating Scale (NRS) Scores (at Rest) Over 72h — 72.30; 66.24; 203.76; 306.58 score on a scale*hour
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 IQOS (Non-Cigarette Tobacco Product) Pilot Study
Smoking · Tobacco Use
Primary: Number of Participants Who Prefer IQOS — 7 Participants
Phase 2 N=222 Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD)
Primary: The Efficacy of SPN-812 on the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) — -10.5; -16.7; -18.4; -18.6 units on a scale — p=0.0899
Phase 2 N=161 Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Alzheimer Disease
Primary: Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R) — -0.09679; -0.15776 Z-score — p=0.564
Phase 3 N=418 Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)
Postoperative Pain
Primary: Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores With Activity (NRS-A) Through 72 Hours Postsurgery (AUC0-72), Compared With…
N/A N=19 Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease
Parkinson's Disease
Primary: Gait Speed (m/s) — 1.14; 1.21; 1.22; 1.20 m/s
N/A N=4 Otteroo Case Series
Infants With or at Risk/Concern for Developmental Delay
Primary: Change in Alberta Infant Motor Scale — 5 change in percentile
N/A N=34 Investigating Compassion-Based Guided Self-Help for Depression in People With Skin Conditions
Dermatologic Disease · Depression
Primary: Acceptability of Intervention Overall — 11 Participants
Phase 2 N=3 Afamelanotide in Patients Suffering With Acne Vulgaris
Acne Vulgaris
Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
Phase 2 N=109 A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Objective Response (Cohort 1) — 70.1 Percentage of participants — p=<0.0001
Phase 2 N=25 Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
Primary: Number of Participants With Acute Toxicity — 23 Participants
Phase 2 N=10 RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia
Male Infertility, Azoospermia
Primary: Total Motile Sperm — 8; 1 Participants
Phase 4 N=30 Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
Device Latency
Primary: Percentage of Participants With Accuracy of Ingestible Event Marker (IEM) Detection — 73.3; 63.3; 76.7; 93.3 percentage of participants
N/A N=112 Fibrin Melanoma Axillary Node Study in Patients With Melanoma
Melanoma
Primary: Drain Duration — 23; 21 days